GGrantIndex
Sort

64,565 grants matching drug discovery

Discovery of novel flavivirus inhibitors

$2,677,020
Fumiaki Yokokawa · University Of Texas Med Br Galveston · U19 · FY2022 · AI

Comprehensive Cancer Center Program at Fox Chase

$2,675,570
Richard I Fisher · Research Inst Of Fox Chase Can Ctr · P30 · FY2016 · CA

Structure-function relationships in alpha-synuclein strain biology

$2,674,385
Amanda L. Woerman · Colorado State University · RF1 · FY2025 · NS

Whole Genome Sequencing to Identify Causal Genetic Variants Influencing CVD Risk

$2,673,849
John Blangero · Texas Biomedical Research Institute · R01 · FY2014 · HL

Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes

$2,669,672
Isabel Lauren Jackson · University Of Maryland Baltimore · U19 · FY2021 · AI

FAMU RCMI Pharmaceutical Research Center

$2,669,457
Karam F.a. Soliman · Florida Agricultural And Mechanical Univ · G12 · FY2015 · MD

Implantable, Degradable Drug Delivery Devices for Non-Opioid Post-Surgical Pain Management

$2,668,301
Kelly Anne Burke · University Of Connecticut Storrs · R18 · FY2025 · EB

Asthma Inflammation Research

$2,667,320
Serpil C. Erzurum · Cleveland Clinic Lerner Com-Cwru · P01 · FY2016 · HL

CTSA INFRASTRUCTURE FOR AIDS RESEARCH

$2,664,477
Daniel Ernest Ford · Johns Hopkins University · UL1 · FY2009 · RR

CTSA INFRASTRUCTURE FOR AIDS RESEARCH

$2,664,477
Daniel Ernest Ford · Johns Hopkins University · UL1 · FY2009 · RR

Pharmacogenomics of Arrhythmia Therapy

$2,658,629
Dan M Roden · Vanderbilt University · U01 · FY2008 · HL

Moffitt Cancer Center Support Grant

$2,657,144
William S. Dalton · H. Lee Moffitt Cancer Ctr & Res Inst · P30 · FY2011 · CA

A Neural Systems Approach to Monitoring and Drug-Delivery for General Anesthesia

$2,654,750
Patrick L. Purdon · Massachusetts General Hospital · DP2 · FY2009 · OD

NCI-Frederick Support and Technical Services

$2,653,485
Kristin Komschlies McConville · Office Of The Director, Nci · ZIC · FY2023 · CA

Scientific Core - Compound Optimization and Prioritization.

$2,652,211
Anna Upton · Global Alliance For Tb Drug Development · U19 · FY2021 · AI

Center of Catalytic Bioscanvenger Medical Defense Research II: Discovery, Formula

$2,650,595
Douglas Mark Cerasoli · U.S. Army Medical Research Inst Chem Def · U54 · FY2011 · NS

Pharmacogenomics of Arrhythmia Therapy

$2,647,864
Dan M Roden · Vanderbilt University · U01 · FY2006 · HL

Preclinical studies for the development of selective mGlu2 positive allosteric modulators to treat substance use disorders

$2,646,217
Nicholas David Cosford · Sanford Burnham Prebys Medical Discovery Institute · U01 · FY2017 · DA

3D Bioprinting of human native-like tissues as disease-in-a-dish models for drug discovery

$2,644,877
Marc Ferrer-Alegre · National Center For Advancing Translational Sciences · ZIA · FY2019 · TR

The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development

$2,644,617
Craig Lindsley · Vanderbilt University · U54 · FY2013 · MH

Pharmacogenomics of Arrhythmia Therapy

$2,644,284
Dan M Roden · Vanderbilt University · U01 · FY2007 · HL

iPSC-based platform development for major psychiatric disorder modeling and discovery

$2,643,131
Hongjun Song · University Of Pennsylvania · U19 · FY2017 · MH

The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes

$2,641,849
Laura J Esserman · University Of California, San Francisco · P01 · FY2024 · CA

Genetic variant-based drug discovery targeting conserved pathways of aging

$2,640,750
Jan No Middle Name Vijg · Albert Einstein College Of Medicine · U19 · FY2025 · AG

Host Pathogen Variation & TB Pathogenesis

$2,638,886
Thomas R Hawn · University Of Washington · U19 · FY2021 · AI